Linked Life Data

1356277

Source:http://linkedlifedata.com/resource/pubmed/id/1356277

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1992-10-22
pubmed:abstractText
The physiologcal and psychological effects of the novel imidazo-pyridine alpidem were compared with those of the benzodiazepine lorazepam in the context of a clinical trial. Twenty-three psychiatric out-patients with generalised anxiety disorder received alpidem (mean dose 112.5 mg daily) or lorazepam (mean 3.5 mg daily) in doses adjusted to clinical need under double-blind conditions. A battery of tests was performed before and after four weeks treatment. Anxiety scores improved very significantly in both groups with no subjective sedation nor other particular side-effects noted in either group. However, lorazepam reduced the EEG averaged evoked response and produced significant impairment in the reaction time and memory tests whereas alpidem had no such effects. Alpidem therefore shows promise as an effective anxiolytic devoid of the adverse psychomotor and cognitive effects often associated with the benzodiazepines.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0176-3679
pubmed:author
pubmed:issnType
Print
pubmed:volume
25
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
177-81
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1992
pubmed:articleTitle
Alpidem and lorazepam in the treatment of patients with anxiety disorders: comparison of physiological and psychological effects.
pubmed:affiliation
Institute of Psychiatry, London, Great Britain.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't